GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short - Investor's Business Daily

GSK (GSK) stock crumbled Friday after the Food and Drug Administration granted its blood cancer treatment, Blenrep, a narrower-than-expected approval. The agency signed off on several combinations u…